9 completed, 2 active not recruiting, 1 recruiting, 1 unknown. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
Follow BPGbio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) BPM31510, Vitamin K1, Temozolomide (TMZ) - Glioblastoma, Glioblastoma Multiforme | Phase 2 | Active not recruiting | BPGbio | 50 | 2022-08-22 | 2026-01-26 |
| AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) Standard of care liver biopsy, Fibroscan, Biospecimen Collection - Non-Alcoholic Fatty Liver Disease | Recruiting | AdventHealth Translational Research Institute | 1250 | 2021-04-22 | 2025-03-13 | |
| Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma Glioblastoma | Active not recruiting | BPGbio | 150 | 2021-03-01 | 2026-07-01 | |
| A Safety Study of Orally Administered BPM31510 in Healthy Subjects BPM31510 Oral Nanosuspension 4% - Healthy | Phase 1 | Completed | BPGbio | 25 | 2017-01-01 | 2017-04-05 |
| Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa topical BPM31510 3.0% Cream - Epidermolysis Bullosa | Phase 1 | Completed | Shasa Hu | 11 | 2016-08-10 | 2020-06-16 |
| BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients BPM31510 Nanosuspension Injection, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | BPGbio | 45 | 2016-07-06 | 2025-03-26 |
| Project Survival-Prospective Biomarker Discovery Pancreatic Neoplasms, Pancreatic Cancer | Unknown | Pancreatic Cancer Research Team | 436 | 2016-03-01 | 2019-04-16 | |
| A Safety Study of Orally Administered BPM31510 in Healthy Subjects BPM31510 Oral Nanosuspension 4% - Healthy | Phase 1 | Completed | BPGbio | 20 | 2015-11-01 | 2016-12-22 |
| BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors BP31510 monotherapy, BP31510 in combination with chemotherapy - Metastatic Cancer, Cancer | Phase 1 | Completed | BPGbio | 97 | 2013-10-01 | 2025-02-19 |
| Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL - Chemotherapy-Induced Alopecia | Phase 1 | Completed | BPGbio | 28 | 2012-09-17 | 2026-08-17 |
| Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors Sterile Compound C31510 for Injection - Solid Tumors | Phase 1 | Completed | BPGbio | 50 | 2011-01-01 | 2025-02-19 |
| An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) API 31510 - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | BPGbio | 35 | 2008-06-01 | 2019-03-05 |
| Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma API 31510 3% Topical Cream, API 31510 1.5% Topical Cream, Placebo - Superficial Basal Cell Carcinoma | Phase 1 / Phase 2 | Completed | BPGbio | 186 | 2008-03-01 | 2025-02-28 |
| Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma API 31510 Topical Cream - Squamous Cell Carcinoma | Phase 2 | Withdrawn | BPGbio | 2008-03-01 | 2012-07-25 |
Carcinoma, Squamous Cell (2) · Glioblastoma (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Alopecia (1) · Brain Neoplasms (1) · Epidermolysis Bullosa (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Non-alcoholic Fatty Liver Disease (1) · Pancreatic Diseases (1) · Pancreatitis (1)
coenzyme Q10 (3) · Calcitriol (1) · Drug Therapy (1) · Gemcitabine (1) · Injections (1) · Radiation (1) · Temozolomide (1) · Vitamin K 1 (1)
United States (13) · United Kingdom (1)
Magdy Shenouda, MD (2) · A. James Moser, MD (1) · David Wilson, MD (1) · Karen Corbin, PhD, RD (1) · Kim-Son Nguyen, MD (1) · Manish A Shah, MD (1) · Mario E Lacouture, MD (1) · Monica Mita, MD (1) · Ramesh K Ramanathan, MD (1) · Shari Goldfarb, MD (1) · Tomislav Dragovich, MD (1) · Tracy J Mayne, PhD (1) · Vivek Subbiah, MD (1)